In short
Clinical trials are studying Satralizumab in different patient groups, including people with type 1 facioscapulohumeral muscular dystrophy and children with AQP4 antibody-positive neuromyelitis optica spectrum disorder. These studies aim to assess efficacy, safety, tolerability, and in one trial, pharmacokinetics in young children.
Key points
- Clinical trials of Satralizumab are being done in two main groups: people with type 1 facioscapulohumeral muscular dystrophy and children with AQP4 antibody-positive neuromyelitis optica spectrum disorder. The FSHD1 study is a Phase 2 trial that compares Satralizumab with placebo and measures many outcomes, including muscle MRI, strength, disability, falls, and safety. The pediatric NMOSD study is a Phase 3 trial in children aged 2 to 11 years and focuses on pharmacokinetics, which means how the body handles the drug. Both trials are authorised and are interventional studies. The trial data show that researchers are looking at both benefit and safety, but in different diseases and age groups.
Trial overview
The trial data include two authorised interventional studies of Satralizumab. One study is in type 1 facioscapulohumeral muscular dystrophy (FSHD1), and the other is in neuromyelitis optica spectrum disorder (NMOSD) in children with AQP4 antibodies. Both studies are designed to learn more about how well Satralizumab works and how safe it is in the target group, while the pediatric study also looks at pharmacokinetics.
Phase 2 study in FSHD1
The first study is a randomized trial, which means participants are assigned by chance to a treatment group, and it is double blind, which means the participants and study team do not know who gets which treatment during the blinded period. It is also placebo-controlled, so Satralizumab is compared with a placebo that looks the same but does not contain the active ingredient. This Phase 2 study is designed for people with FSHD1 and plans to enroll 46 participants.
The main goal is to compare Satralizumab with placebo over 48 weeks of the double-blind period. Researchers want to see whether Satralizumab changes whole body muscle MRI findings, the RICCI clinical severity scale, reachable work space, muscle strength, the FSHD-Composite Outcome Measure, and the FSHD-Rasch-built overall disability scale. They also assess patient-reported and clinician-reported change scales, the number of falls, upper-limb and walking independence, inflammation markers, and safety outcomes.
The safety part of this study looks at the type, frequency, severity, and seriousness of adverse events, which are unwanted medical events that happen during a study. It also checks adverse events of special interest, study drug discontinuation because of an adverse event, and changes in laboratory tests, vital signs, and physical examination results.
Phase 3 study in pediatric NMOSD
The second trial is a Phase 3 study in pediatric patients with AQP4 antibody-positive NMOSD. It plans to enroll 21 children aged 2 to 11 years. This study is focused on pharmacokinetics, efficacy, safety, tolerability, and pharmacodynamics, which means how the drug behaves in the body and what effects it may have.
The main outcomes are serum concentration measurements at specific trough timepoints and population and individual estimates of pharmacokinetic parameters using a population-PK model. In simple words, the study measures how much Satralizumab is in the blood at certain times and uses that information to understand drug exposure over 24 weeks.
Outcomes and measures used in the trials
The FSHD1 study uses many outcome measures to capture different parts of the disease. These include imaging of muscles with MRI, clinical severity scoring, movement range, strength testing, disability scales, and the number of falls. It also looks at inflammation-related molecular biomarkers such as IFN-γ, IL-1β, IL-6, TNF-α, VEGF, IL1-RA, IL-6-R, sICAM-1, sVCAM-1, and SAA.
The pediatric NMOSD study has a narrower main focus on blood levels of Satralizumab and pharmacokinetic modeling. This is important because younger children may handle medicines differently from older children or adults.
What participants should know from the trial data
From the trial records, the FSHD1 study is a comparison between Satralizumab and placebo, while the pediatric NMOSD study gives Satralizumab to children and measures how the body processes it. The studies are not in the same disease, age group, or phase, so they answer different research questions. Together, they show that researchers are testing Satralizumab in both a rare muscle disease and a rare nervous system disease.